바이오콘 바이오로직스, 비아트리스 바이오시밀러 사업 통합 완료…세계 최대 기업으로 부상

This integration significantly bolsters India's position as a global biosimilars manufacturing and export hub, benefiting the broader APAC supply chain. For emerging Asian markets like Indonesia, Vietnam, and the Philippines, Biocon's expanded scale promises increased access to affordable cancer and autoimmune treatments, potentially impacting local healthcare budgets and competitive dynamics for regional pharmaceutical players. Monitor potential regulatory shifts in these markets to accommodate accelerated biosimilar approvals.